Summary.-Ethyl-a-p-chlorophenoxyisobutyrate (clofibrate), a hypolipidaemic drug which induces hepatomegaly and proliferation of peroxisomes in liver cells of rats and mice, was fed to 15 male F344 rats at a dietary concentration of 0.5%o (v/w) for up to 28 months. Hepatocellular carcinomas developed in 10/11 (91 ,h) rats killed between 24 and 28 months. Other tumours included carcinoma of the pancreas (2 rats), leiomyoma of the small intestine (1 rat) and a large dermatofibrosarcoma (1 rat). Clofibrate is the third hypolipidaemic peroxisome proliferator demonstrated to be hepatocarcinogenic in rats. These studies suggest that hypolipidaemic agents which are capable of producing a sustained hepatomegalic and peroxisome-proliferative effect also induce liver tumours.
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ETHYL o-p-chlorophenoxyisobutyrate (clofibrate, Fig. 1 ), which modifies lipid metabolism (Thorp, 1962; Thorp & Waring, 1962) , is widely used in the treatment of hyperlipidaemia in an effort to prevent ischaemic heart disease (Yeshurun & Gotto, 1976;  Lees & Lees, 1976; Carlson et al., 1977) . Clofibrate induces the proliferation of peroxisomes in liver cells in rats and mice, and this effect is sustained as long as the compound is administered (Hess et al., 1965; Svoboda & Azarnoff, 1966; Reddy et al., 1969) . Since hypolipidaemic drugs such as clofibrate are being administered clinically for long periods (Finkel, 1977) (Reddy et al., 1976 (Reddy et al., , 1979 Reddy & Rao, 1977 The control animals were fed the same chow witlhout the drug, and include animals serving as long-term conitrols for chrlonic studies with otlher peroxisome proliferators.
t Number of animals killed between 24 and 28 months.
I In relation to the effectiVe number. Significantly different (P < 0-001) from animals fed control diet, as dcetermine(I by x2 test -with 1 degree of fi-eedom. § Occurring concurrently in animals writh liv-er tumours.
samples of liver and liver tumours were fixed in cold 255% glutaraldehyde in 0 1M cacodylate buffer, pH 7 4, for 30-60 min and then post-fixed for 1 h in 1% OS04 in 0d1M
S-collidine buffer, pH 7-4. After fixation, the tissues were dehydrated in ethanol and processed as described previously (Reddy et al., 1974b) . For cytochemnical localization of peroxisome catalase, selected samples of liver and liver tumours w-ere processed as described by Novikoff & Goldfischer (1969 showed pulmonary metastases (Fig. 3) .
The primary hepatocellular carcinomas varied in their ultrastructural differentiation, but many tumour cells contained prominent peroxisomes (Fig. 4) . Among the other tumours found in clofibrate-fed animals were pancreatic acinar carcinoma (2 rats), leiomyoma of the ileuim (1 rat) and dermatofibrosarcoma (2 rats). The 2 pancreatic acinar carcinomas (Figs. 5 and 6) measured 1-5 and 2*0 cm in diameter respectively, and invaded the greater curvature of t,he stomach in both rats. One of these tumours metastasized to the liver. The leiomyoma of the ileum (8 mm in diameter) and the dermatofibrosarcoma of the skin (6 cm in diameter) were well differentiated.
DISCUSSION
The relationship of hyperlipidaemia to prevalence, incidence and mortality from ischaemic heart disease has been well established (Stamler et al., 1960; Kannel et al., 1971) . The results of the WHOsponsored clinical trial of the effects of lowering blood cholesterol by therapeutic intervention with clofibrate in the prevention of ischaemic heart disease clearly demonstrate that reduction of serum cholesterol concentrations is relevant to the prevention of coronary heart disease (Committee of Principal Investigators, 1978) . Despite a significant reduction in the incidence of ischaemic heart disease in this study, there were, however, significantly more deaths from all causes, including malignant neoplasms, in the clofibrate group than in the high-cholesterol control group (ibid). It is not clear whether the increased incidence of malignant neoplasms, particularly in the gastrointestinal tract and pancreas, is due to the carcinogenic effect of clofibrate or is secondary to mobilization of cholesterol from body pools, leading to increased levels of faecal sterols and bile acids (Oliver, 1978) or due to some other mechanism. Secondary bile acids appear to enhance carcinogenesis in rat colon (Reddy et al., 1974) . The hypocholesterolaemic agents cholestyramine and candicin have been shown to promote the development of intestinal tumours in rats by altering the faecal bile acids and cholesterol (Nigro et al., 1977) . Whatever may be the mechanism of increased incidence of tumours, either in clofibrate-treated individuals in the WHO-sponsored study cited above, or in 2 other major primary prevention trials in which dietary means for the reduction of serum cholesterol were used (Dayton et al., 1969; Miettinen et al., 1972 ), it appears necessary to demonstrate long-term safety for both new and already marketed hypolipidaemic drugs (Finkel, 1977) if these drugs are to be indicated for the treatment of hypertriglyceridaemia refractory to dietary management (Lees, 1979) .
The results of the present study demonstrate that dietary exposure to clofibrate produced hepatocellular tumours in male F344 rats. Although the number of animals used in these experiments is small, the liver-tumour incidence in clofibratefed animals, according to x2 analysis, is significantly different from that in controls (P < 0-001). In addition, pancreatic acinar carcinomas developed in 2 rats, leiomyoma of the ileum in 1 rat, and dermatofibrosarcoma in 1 rat. It is questionable whether the solitary leiomyoma of the ileum and the large dermatofibrosarcoma are induced by clofibrate, because aged F344 rats occasionally develop spontaneous subcutaneous fibromas and fibrosarcomas (Sass et al., 1975) . The pancreatic acinar cell carcinomas in 2 rats may, however, be attributable to clofibrate since spontaneously occurring malignant exocrine pancreatic neoplasms have not been found in any F344 rats during the past 10 years in our laboratory. In an earlier study, 20%
(3/15) of F344 rats developed pancreatic acinar-cell neoplasms when fed nafenopin, a potent hypolipidaemic peroxisome proliferator which is structurally related to clofibrate (Reddy & Rao, 1977) , suggesting that these hypolipidaemic agents also exert a carcinogenic effect in other organs besides the liver.
Little is known of the mechanism by wvhich clofibrate exerts its effect in the initiation or promotion of liver tumour (Reddy & Rao, 1978) . This is now the third hypolipidaemic hepatic-peroxisome proliferator (Reddy & Krishnakantha, 1975) , shown to be carcinogenic in rats. The possible relationship of mitogenic effect, persistent peroxisome proliferation annd hepatomegaly to hepatocarcinogenicity has been considered (Reddy et al., 1976 (Reddy et al., , 1979 . Possible direct interactions of hypolipidaemic agents which induce hepatic peroxisome proliferation with cellular DNA have recently been examined, using both prokaryotic and eukaryotic cell in vitro assay systems. None of the drugs studied (including clofibrate, Wy-14,643 and nafenopin, which have been demonstrated to be hepatocarcinogenic) were mutagenic (Warren, J. R ., unpublished) in the Ames Salmonella/microsome reversemutation assay (McCann et al., 1975) . In addition, these hypolipidaemic agents, added without or with a liver S-9 metabolic-activation system to in vitro cultures of proliferating lymphocytes (Warren, 1978) , failed to inhibit DNA replication irreversibly (Warren, J. R., unpublished) . It appears therefore that neither the hypolipidaemic agents nor their metabolites are capable of interacting directly with cellular DNA. However, further experimental data, such as information on the covalent binding of these agents with liver macromolecules and the use of other biological systems for carcinogenicity assay, are required to explain this divergence between in vitro and in vivo findings. The possibility that the hypolipidaemic compounds induce hepatocellular carcinomas in rats and mice via a non-genetic mechanism similar to that advanced for saccharin (Ashby et al., 1978 ) cannot be ruled out.
